Shares of Immunomedics Inc. (NASDAQ:IMMU) fell 0.3% during trading on Tuesday . The stock traded as low as $2.90 and last traded at $2.97, with a volume of 1,011,941 shares changing hands. The stock had previously closed at $2.98.

Several research firms recently commented on IMMU. Wells Fargo & Co. downgraded shares of Immunomedics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, June 21st. Jefferies Group reiterated a “buy” rating and issued a $5.00 price target on shares of Immunomedics in a research report on Monday, June 6th. Finally, Zacks Investment Research downgraded shares of Immunomedics from a “buy” rating to a “sell” rating in a research report on Tuesday, May 10th.

The stock’s market capitalization is $284.72 million. The company has a 50-day moving average price of $2.65 and a 200 day moving average price of $2.89.

Immunomedics (NASDAQ:IMMU) last posted its quarterly earnings data on Wednesday, August 17th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by $0.06. Analysts expect that Immunomedics Inc. will post ($0.47) earnings per share for the current year.

In other news, CEO Cynthia L. Goldenberg sold 371,990 shares of the firm’s stock in a transaction that occurred on Monday, June 13th. The shares were sold at an average price of $3.03, for a total transaction of $1,127,129.70. Following the completion of the sale, the chief executive officer now owns 650,396 shares of the company’s stock, valued at $1,970,699.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman David M. Goldenberg sold 353,010 shares of the firm’s stock in a transaction that occurred on Wednesday, June 8th. The stock was sold at an average price of $3.88, for a total transaction of $1,369,678.80. Following the sale, the chairman now directly owns 2,602,063 shares of the company’s stock, valued at approximately $10,096,004.44. The disclosure for this sale can be found here.

A hedge fund recently bought a new stake in Immunomedics stock. Marshall Wace LLP purchased a new position in Immunomedics Inc. (NASDAQ:IMMU) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 857,062 shares of the biopharmaceutical company’s stock, valued at approximately $2,631,000. Marshall Wace LLP owned approximately 0.90% of Immunomedics at the end of the most recent reporting period.

Immunomedics, Inc is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. The Company’s technologies allow it to create humanized antibodies in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.